Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …

Background We studied humoral responses after coronavirus disease 2019 (COVID-19)
vaccination across varying causes of immunodeficiency. Methods Prospective study of fully …

Importance The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and
sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-…

Importance Monoclonal antibody (mAb) treatment decreases hospitalization and death in
high-risk outpatients with mild to moderate COVID-19; however, only intravenous …

Background Monoclonal antibody (mAb) treatment is associated with decreased risk of
hospitalization and death in high-risk outpatients with mild to moderate coronavirus disease 2019 …

Objective COVID-19 disproportionately impacts residents in long-term care facilities. Our
objective was to quantify the presence and magnitude of antibody response in vaccinated, …

Objectives Immunocompromised patients were excluded from COVID-19 vaccine clinical
trials. The objectives of the study were to measure antibody responses, levels, and …

IMPORTANCE The effectiveness of monoclonal antibodies (mAbs), casirivimab and imdevimab,
and sotrovimab, for patients with mild to moderate COVID-19 from the Delta variant is …

Background Monoclonal antibodies (mAb) that neutralize SARS-CoV-2 decrease hospitalization
and death compared to placebo in patients with mild to moderate COVID-19; however, …

Background Neutralizing monoclonal antibodies (mAb) targeting SARS-CoV-2 decrease
hospitalization and death in patients with mild to moderate Covid-19. Yet, their clinical use is …